Skip to main content
Chengdu Easton Bio Pharmaceuticals Co.,Ltd logo

Chengdu Easton Bio Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 688513 ISIN · CNE100004397 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 696 across all filing types
Latest filing 2026-05-28 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688513

About Chengdu Easton Bio Pharmaceuticals Co.,Ltd

http://www.eastonpharma.cn/en/

Chengdu Easton Bio Pharmaceuticals Co., Ltd. focuses on the research, development, production, and commercialization of chemical APIs and finished dosage forms. The company specializes in therapeutic fields including cardiovascular, anesthesia, analgesia, digestive system, and diabetes management. Its portfolio comprises high-end generic medications and complex formulations developed to align with international quality standards. Operating under stringent Good Manufacturing Practice (GMP) protocols, the firm utilizes advanced technology platforms to produce a variety of injections and oral solid dosages. The organization prioritizes innovation through a dedicated R&D infrastructure, targeting the creation of value-added medicines and high-barrier generics. Its operations integrate the entire value chain from laboratory synthesis to large-scale manufacturing and market distribution.

Recent filings

Filing Released Lang Actions
苑东生物：2026年限制性股票激励计划实施考核管理办法
Governance Information Classification · 82% confidence The document is titled “2026年限制性股票激励计划实施考核管理办法” and contains detailed internal rules and governance procedures for a restricted stock incentive plan, outlining objectives, principles, assessment mechanisms, responsibilities, and vesting criteria. It does not present financial results or regulatory filings, nor is it announcing results or a report publication. This is a corporate governance policy document prescribing internal rules and processes. Therefore, it fits the Governance Information category (CGR).
2026-05-28 Chinese
苑东生物：2026年限制性股票激励计划（草案）摘要公告
Share Issue/Capital Change Classification · 65% confidence The document is a detailed summary announcement of Chengdu Yuandong Biotech’s 2026 restricted stock incentive plan (“限制性股票激励计划草案摘要公告”). It outlines the share-based compensation scheme, number of shares, vesting conditions, pricing methodology, performance targets, and governance procedures for granting treasury shares to employees and directors. This is not an earnings release, annual report, call transcript, audit report, or a proxy solicitation per se, but rather an announcement of a corporate equity incentive plan involving share allocation. Under our taxonomy, share‐based compensation arrangements are best captured by the Share Issue/Capital Change category (SHA), since it fundamentally alters the company’s share capital structure through issuance (or re‐allocation) of shares to employees.
2026-05-28 Chinese
苑东生物：第四届董事会第十二次会议决议公告
Regulatory Filings Classification · 85% confidence The document is a formal announcement of the board of directors’ meeting resolutions (“第四届董事会第十二次会议决议公告”), detailing the convening of the meeting, attendance, specific proposals approved, and next steps (e.g., submitting matters to a shareholders’ meeting). It does not itself change board membership or senior management, nor does it contain financial statements, regulatory certifications, or notice of dividends. There is no transcript, audit report, or detailed investor presentation. Because it is a corporate regulatory announcement that does not fit any more specialized category, it falls under the fallback category of Regulatory Filings (RNS).
2026-05-28 Chinese
苑东生物：关于自愿披露维生素K?注射液获得药品注册证书的公告
Regulatory Filings Classification · 90% confidence The document is a voluntary disclosure announcement by Chengdu Yuandong Biopharma regarding receipt of a drug registration certificate from the National Medical Products Administration. It contains no financial statements or report attachments, nor is it a call transcript, AGM material, earnings release, or management report. It is a general regulatory announcement complying with disclosure requirements. Therefore it falls under Regulatory Filings (RNS).
2026-05-22 Chinese
苑东生物：关于注销部分募集资金专项账户的公告
Regulatory Filings Classification · 85% confidence The document is a formal exchange announcement by Chengdu Yuandong Biopharma regarding the cancellation of a special fundraising bank account established as part of its 2020 IPO proceeds. It provides details on the original fundraising, account usage, and the specific account closure. It does not contain financial statements or constitute an annual or interim report, nor is it a notice of dividend, share issue, board change, or merger. It is a compliance/regulatory disclosure that does not fit into any other specialized category, making “Regulatory Filings (RNS)” the most appropriate classification.
2026-05-18 Chinese
苑东生物：2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a formal announcement of the 2025 Annual General Meeting resolutions for Chengdu Yuandong Bio-Pharma Co., Ltd., including detailed voting results for each proposal, meeting attendance, and legal compliance statements. It reports the outcome of shareholder votes at an AGM. Therefore, it fits the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-13 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.